FDA Drug Safety Communication: Eosinophilic pneumonia associated with the use of Cubicin (daptomycin)
This is a discussion on FDA Drug Safety Communication: Eosinophilic pneumonia associated with the use of Cubicin (daptomycin) within the FDA News forum, part of the Industry News and Updates category; More......
|
|||||||
| Register | Help | Members List | Mark Forums Read |
07-29-2010, 01:39 PM
|
|||
|
|||
FDA Drug Safety Communication: Eosinophilic pneumonia associated with the use of Cubicin (daptomycin)
|
 |
«
Previous Thread
|
Next Thread
»
| Thread Tools | |
| Display Modes | |
Linear Mode
|
|
|
||||
| Thread | Thread Starter | Forum | Replies | Last Post |
| FDA Drug Safety Communication: Ongoing safety review of Evamist (estradiol transdermal spray) and unintended exposure of | industry_news | FDA News | 0 | 07-29-2010 03:18 PM |
| FDA Drug Safety Communication: Ongoing safety review of Benicar and cardiovascular events | industry_news | FDA News | 0 | 06-11-2010 01:06 PM |
| FDA Drug Safety Communication: Ongoing Safety Review of Stalevo (entacapone/carbidopa/levodopa) and possible development | industry_news | FDA News | 0 | 03-31-2010 02:28 PM |
| FDA Drug Safety Communication: Ongoing safety review of oral bisphosphonates and atypical subtrochanteric femur fracture | industry_news | FDA News | 0 | 03-10-2010 03:42 PM |
| FDA Drug Safety Communication: Ongoing safety review of Invirase (saquinavir) and possible association with abnormal hea | industry_news | FDA News | 0 | 02-23-2010 12:59 PM |
© 2008 DrugManagementForum™ powered by |
 |